MyLymphomaTeam

The cure time and outcomes for Double Hit Lymphoma (DHL) following CAR T-cell therapy like Yescarta can vary significantly between patients. Studies show that after two years, approximately 50% of people with DHL were still alive, with 40% showing no signs of disease progression.

CAR T-cell therapy has been a Show Full Answer

The cure time and outcomes for Double Hit Lymphoma (DHL) following CAR T-cell therapy like Yescarta can vary significantly between patients. Studies show that after two years, approximately 50% of people with DHL were still alive, with 40% showing no signs of disease progression.

CAR T-cell therapy has been a practice-changing development, offering a chance of cure for some patients whose lymphomas haven't responded to other treatments. It's important to note that DHL is often diagnosed at an advanced stage and can be refractory (non-responsive) to treatment. While CAR T-cell therapy represents a promising treatment option, the response varies by individual. Regular follow-up with your healthcare team is essential to monitor your specific response to treatment.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Advances in Lymphoma Research: A Discussion With Dr. Dean

What Is Double-Hit Lymphoma? Symptoms, Survival Rate, and More